Royalty Report: Drugs, Cancer, Disease – Collection: 5297

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 12

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Diagnostic
  • Biotechnology
  • Diagnostic Substances
  • Genome
  • Therapeutic
  • Drug Discovery
  • Cell Line
  • Antibody

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 5297

License Grant
Licensor hereby grants the right to use MoAb 7E11-C.5.3 solely for such purposes.
License Property
The term 'MoAb 7E11 shall mean and collectively include that certain antibody to PSMA known as MoAb 7E11-C5, which such antibody is claimed in United States Patent No 5,162,504, granted November 10, 1992, and entitled 'Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostate Cancer Patients.'  One subclone of MoAb 7E11 is MoAb 7E11-C5.3.  To enable the licensee to utilize MoAb 7E11-C 5.3 in connection with the development, manufacturing, testing, or conducting quality control tests on Licensed Products and to practice Licensed Processes.
Field of Use
The term 'PSMA' shall mean prostate specific membrane antigen and shall include the PSMA protein.

The term 'PSMP' shall mean prostate specific membrane peptides which shall include any peptide sequence appearing within the PSMA protein.

The term 'Licensed Products' shall mean products for the immunotherapy of prostate cancer which are produced by [  ***  ], with a composition including PSMA and/or PSMP, and/or the mimetopes of PSMA or PSMP.

The term 'Licensed Processes' shall mean any process for the immunotherapy of prostate cancer in patients by [  ***  ] including, but not limited to [  ***  ], ex vivo, with a composition including PSMA and/or PSMP, and/or the mimetopes of PSMA or PSMP, and [  ***  ] the use or practice of which would, but for the licenses granted herein, infringe one or more Valid Claims of an issued patent or pending patent application included in SKICR Patent Rights.

IPSCIO Record ID: 356291

License Grant
For the General Grant to the German Licensee, Licensor grants an exclusive license, including the right to sublicense through multiple tiers, under the Licensor Technology, Licensor Platform Technology, Licensor Manufacturing Technology and Licensors interest in the Joint Technology, to Develop the Product in the Licensees Territory in the Field; and during the Term, an exclusive license, including the right to sublicense through multiple tiers, under the Licensor Technology, Licensor Platform Technology, Licensor Manufacturing Technology and Licensors interest in the Joint Technology, to Commercialize the Product in the Field in the Licensees Territory; and during the Term, a non-exclusive, perpetual, worldwide license under the Licensor Technology, Licensor Platform Technology, Licensor Manufacturing Technology and Licensors interest in the Joint Technology, to perform Development Activities in the Licensor Territory solely in accordance with the Development Plan and for Sole-Funded Activities by Licensee.

For the Manufacturing Grant to Licensee, Licensor grants a co-exclusive license, including the right to sublicense through multiple tiers, under the Licensor Manufacturing Technology, Licensors interest in the Joint Technology, Licensor Patents and the Licensor Platform Technology, to Manufacture the Product for Development worldwide in the Field and for Commercialization in the Field in the Licensee Territory.

By this agreement, Licensor will have the exclusive commercialization rights in the United States and Canada and Licensee will have the exclusive commercialization rights in the rest of the world.

License Property
Licensor has developed and is currently further developing the novel compound xx414.

Compound xx414 means a bispecific polypeptide containing a Prostate Specific Membrane Antigen or PSMA Binding derived from murine antibody 107-1A4 and a CD3 Binding Domain derived from murine antibody CRIS-7 (xx414), and any back-up or follow-on compound comprised of a PSMA Binding Domain with or without other Binding Domains, including both a PSMA Binding Domain and a CD3 Binding Domain or both a PSMA Binding Domain and a Binding Domain other than CD3 Binding Domain; and any modification or derivative of the foregoing (including conjugated or mono/multi-specific forms thereof).

CD3 Antigen means the T cell receptor (TCR) complex or any one or more of the CD3 group of cell surface molecules found on T-cells, including TCRa, TCRb, CD3y, CD3d, and CD3e.

CD3 Binding Domain means a Binding Domain that binds the CD3 Antigen and which has greater binding selectivity for the CD3 Antigen versus other antigens (and, for purposes of this definition, disregarding any residual binding activity).

Product Inventions means all Inventions relating to a PSMA Binding Domain, including Inventions relating to composition of matter, method of use and method of manufacture of the Product.

PSMA Antigen means prostate specific membrane antigen (PSMA), also known as the enzyme glutamate carboxypeptidase II (GCPII), N-acetyl-L-aspartyl-L-glutamate peptidase I (NAALADase I), or NAAG peptidase.

The patents include
Prostate Specific Membrane Antigen Binding Proteins and Related Compositions and Methods,
CD3 Binding Polypeptides, Single Chain Multivalent Binding Proteins with Effector Function, Heterodimer Binding Proteins and Uses Thereof, and, Polypeptides Heterodimers and Uses Thereof.

Field of Use
The collaboration agreement is for the joint worldwide development and commercialization of MOR209/ES414, a targeted immunotherapeutic protein, which activates host T-cell immunity specifically against cancer cells expressing prostate specific membrane antigen, an antigen commonly overexpressed on prostate cancer cells.

Field means all fields of use, including therapeutic, palliative, prophylactic, diagnostic and research use, in human and animals.

Licensee has significant experience in the development of pharmaceutical products;

IPSCIO Record ID: 324838

License Grant
Licensor, a cancer treatment and research institution, grants an exclusive option to take an exclusive world-wide License under Licensed Patents and Technology.

Upon exercise of its option rights, Licensee shall have the exclusive rights in the Territory, with the right to grant sublicenses, to make, have made, use and sell, licensed products utilizing the Licensed Patents and Technology and products utilizing Licensed Technology.

License Property
The patent is titled Prostate-Specific Membrane Antigen.

Gene technology means that part of Licensed technology that pertains to any DNA encoding the prostate specific membrane (PSM) antigen or any portion of the PSM antigen and any DNA, cDNA, and other derivative or portion of said gene that expresses the PSM antigen, including, but not limited to, diagnostic methods employing DNA probes or PCR techniques to detect prostate cancer and gene therapy applications.

Know-how means the skill or ingenuity based upon the body of knowledge and data which comprise all of the methods, processes, designs, engineering information, trade secrets, and other information and data relating to prostate specific membrane (PSM) antigen recognized by the monoclonal antibody Licensees-356, any subunits of such antigen, any other monoclonal antibodies or binding proteins or peptides recognizing such antigen and any gene or gene segment encoding for such antigen or portion of such antigen, Confidential information and Gene technology which Licensor develops, employs in its own activities, or has available for use prior to or during the term of this Agreement.

Licensed technology means information and data relating to prostate specific membrane (PSM) antigen recognized by the monoclonal antibody Licensees -356, any subunits of such antigen, any other monoclonal antibodies or binding proteins or peptides recognizing such antigen and any gene or gene segment encoding for such antigen or portion of such antigen owned by Licensor as of the effective date or acquired during the term of this agreement; including without limitations, inventions, biological materials, computer programs, technical data, apparatus and Know-how, Gene technology and confidential information, whether patentable or unpatentable.

Licensees-356 is a prostate cancer monoclonal antibody conjugate.

Field of Use
The agreement relates to the detection of prostate cancer and gene therapy applications.

The Parties have a development program involving the prostate specific membrane antigen (PSM) and Licensees prostate cancer monoclonal antibody conjugate, -356.

IPSCIO Record ID: 245915

License Grant
The Parties have entered into that certain Collaboration Agreement, with respect to a collaborative research and joint development and profit-sharing commercialization program between the Parties with respect to specified targets, antibodies and technology.

Licensor no longer wishes to jointly pursue with Licensee certain targets and products that at one time fell under the Collaboration Agreement, but instead wishes to permit Licensee to pursue them independently, and for Northwest to have specified rights to pursue certain products relating to some such targets as set forth in greater detail in this Agreement.

Licensee shall have the exclusive right to Exploit Designated Targets, Designated Target Antibodies and Designated Target Products, except to the extent of the licenses to Licensor, and to select, file, own and communicate with applicable governmental authorities regarding any tradenames, trademarks, Regulatory Documentation and Regulatory Approvals for Licensee Designated Products.

Further, Licensor agrees and acknowledges that Licensee shall have the exclusive right to fund any portion of the development and to retain all profit and income derived from the Exploitation of Licensee Designated Products, subject only to the royalties due Licensor.

Licensor irrevocably, perpetually and forever assigns and conveys to Licensee the Licensors entire right, title and interest in and to the Patents, Know-How, Transferred Antibodies, Data, and, In-License Agreement.

For Specific Rights and Privileges of Patent Ownership, Licensee shall have the following specific rights and privileges
–  Licensee shall have the sole and exclusive right, but not the duty, to file, prosecute, maintain and enforce the patent applications and patents within the Designated Target Patents worldwide.
– Licensee shall have the sole and exclusive right, but not the duty, to grant licenses under the Designated Target Patents, subject only to the licenses granted Licensor.
– Licensee shall have the sole and exclusive right, but not the duty, to sue on the Designated Target Patents, and to collect all damages and profits for any past, present and/or future infringements thereof, including any infringement prior to the Effective Date or thereafter.
– Licensee shall have the sole and exclusive right to sell, assign or otherwise transfer to any other entity or entities any or all of the rights relating to the Designated Target Patents assigned and transferred to Licensee here.
–  As between Licensor and Licensee, Licensee shall have the sole and exclusive right to take all measures consistent with or permitted by ownership of the Designated Target Patents.

License Property
Fucosyltransferase Fucosyl GM-1 shall mean the ganglioside fucosyl gm-1 lFucGM-1).

Flt-4 shall mean the gene that is associated with Genbank Accession No, XP 003852 and allelic polymorphisms associated with such genes.

PSMA shall mean prostate specific membrane antigen related to the gene described in Genbank Accession No. NP 004467 and allelic polymorphisms associated with such gene.

CXCR-4 Product shall mean any antibody product, including any Antibody Product, with a therapeutically meaningful binding affinity for CXCR-4.

DCVax-Prostate Product shall mean that version of Licensors proprietary product that was in Phase III clinical trials under IND number BB IND 8602.

Designated Target shall mean each of PSMA , Fucosyl GM-1 or Flt-4 .

Field of Use
The field of use is Flt-4 Diagnostic Field and PSMA Diagnostic Field.  The antibody products are for the diagnosis, prophylaxis or treatment of human diseases or conditions.

The Parties had entered into that certain Collaboration Agreement to develop fully human antibody-based therapeutics for multiple cancers.

The Licensor's lead DCVax product candidate, DCVax-Prostate, is a prostate cancer treatment that is in a pivotal phase III clinical trial.

IPSCIO Record ID: 6345

License Grant
The Company grants an exclusive, worldwide, royalty-bearing License, with the right to subLicense, to make, have made, use, sell and import Licensed Products, which includes finished products used for the detection of the Company’s proprietary prostate cancer biomarkers in both urine and biopsied prostate tissue for differentiating clinically significant prostate cancer from other prostate conditions, and to use Patent Rights and Know-How covering the prostate cancer biomarkers.
License Property
Licensed Product(s) shall mean finished products consisting of one or more nucleic acid detection reagents for the assay of one or more Prostate Marker(s) for use in the Field, the manufacture, use, sale or importation of which, but for the rights granted herein, would infringe a Valid Claim within Patent Rights.

U.S.
7,117,188
Method of Identifying Patterns in Biological Systems and Uses Thereof

U.S.
12/025,724
Biomarkers Upregulated in Prostate Cancer

U.S.
12/242,264
Biomarkers Overexpressed in Prostate Cancer

U.S.
12/327,823
Methods for Screening, Predicting and Monitoring Prostate Cancer

U.S.
12/349,437
Methods for Screening, Predicting and Monitoring Prostate Cancer

Field of Use
Field shall mean the use of a molecular diagnostic assay using the Licensed Prostate Markers in in vitro diagnostics relating to prostate cancer, including the detection of the presence or risk of prostate cancer, or the selection of therapy, or in a Research Application related to prostate cancer.

IPSCIO Record ID: 249076

License Grant
The Parties have entered into that certain Collaboration Agreement, with respect to a collaborative research and joint development and profit-sharing commercialization program between the Parties with respect to specified targets, antibodies and technology.

For the DCVax-Prostate Product,  Licensor grants an exclusive, worldwide, license, with a right to sublicense, to Licensee under the Designated Target IP that relates to PSMA, to research, develop, manufacture, have manufactured, use, sell, offer for sale, import and otherwise commercialize the DCVax-Prostate Product.

For the PSMA Related Diagnostic Products,  Licensor grants an exclusive, worldwide, irrevocable, perpetual, license, with a right to sublicense, to Licensee under the Designated Target IP that relates to, or is necessary to Exploit, Flt-4, to research, develop, manufacture, have manufactured, use, sell, offer for sale, import and otherwise commercialize Licensee Diagnostic Products for the in vitro or in vivo diagnosis of cancer, screening, monitoring, or selection of patients for specific treatment modalities, or for determining the dose of a therapeutic product the Licensee Flt-4 Diagnostic Field, each such Licensee Diagnostic Product, a Licensee Flt-4 Diagnostic Product, and Non-Antibody Products for the in vitro or in vivo diagnosis and treatment of cancer, and Licensor reserves for itself solely the right to research, develop, manufacture, have manufactured, use, sell, offer for sale, import or otherwise commercialize any Reserved Dovetailing Product provided, however, Licensor shall not promote Reserved Dovetailing Products for use in the Northwest Flt-4 Diagnostic Field, including providing written or other materials relating to use of the Reserved Dovetailing Products in the Licensee Flt-4 Diagnostic Field.

For the HuMAb® Licenses, Licensor grants the right to obtain from Licensor five (5) licenses under the HuMAb® Technology to develop, make, have made, use, sell, offer for sale and import on a worldwide basis selected antibody-based products directed against biological targets,  each a Licensee Target, on the terms set forth to this Agreement, used by Licensor in its standard cash-and-carry agreements.

License Property
Fucosyltransferase Fucosyl GM-1 shall mean the ganglioside fucosyl gm-1 FucGM-1.

Flt-4 shall mean the gene that is associated with Genbank Accession No, XP 003852 and allelic polymorphisms associated with such genes.

PSMA shall mean prostate specific membrane antigen related to the gene described in Genbank Accession No. NP 004467 and allelic polymorphisms associated with such gene.

CXCR-4 Product shall mean any antibody product, including any Antibody Product, with a therapeutically meaningful binding affinity for CXCR-4.

DCVax-Prostate Product shall mean that version of Licensors proprietary product that was in Phase III clinical trials under IND number BB IND 8602.

Designated Target shall mean each of PSMA , Fucosyl GM-1 or Flt-4 .

Field of Use
The field of use is Flt-4 Diagnostic Field and  PSMA Diagnostic Field.  The antibody products are for the diagnosis, prophylaxis or treatment of human diseases or conditions.

IPSCIO Record ID: 5426

License Grant
Licensor grants, subject to the terms of this Agreement, to License a worldwide, perpetual and exclusive sublicense to make, use and sell the Protein and Antibodies solely for use with the Mammastatin Serum Assay and  to make, have made, use and sell the Mammastatin Serum Assay and Improvements thereto.

Licensor grants, subject to the terms of this Agreement, to GBI a worldwide, perpetual and non-exclusive sublicense to make, use and create Improvements to Proteins and Antibodies solely in the research, development and sale of additional antibodies and/or diagnostic assays solely for the diagnosis of breast, prostate and/or ovarian cancers.  Also includes  to make, have made, use and create Improvements to the Mammastatin Serum Assay and the Know-How solely in the research, development and sale of Additional Products.

License Property
The Mammastatin Serum Assay is a test to measure Mammastatin levels in the serum of healthy women and breast cancer patients. This assay has been performed in two different formats with different antibody formats.

Licensor is the owner of certain prostate and ovarian diagnostic technology and related Know-How

P&O TECHNOLOGY shall mean any assay developed by Licensor, or any other agent that Licensor co-operates with that utilizes antibodies against other epithelial cell growth inhibitors of the Mammastatin family of proteins for detection or measurement of a protein that has diagnostic relevance for Prostate and Ovarian Cancer. These diagnostic assays also include any assay developed by Licensor, or any other agent that BIOTHERAPIES cooperates with, that utilizes DNA sequences homologous to the Mammastatin family, and any Know-How that was possessed by Licensor at the time of this Agreement, to measure a biological marker for diagnosis of Prostate or Ovarian Cancer or measuring the risk assessment values of a subject's developing Prostate or Ovarian Cancer.

IPSCIO Record ID: 3789

License Grant
The Company entered into an agreement with Licensee, the former Board of Directors and as the Company’s President and Chief Scientific Officer, for certain patents regarding the molecular diagnostic technology platforms.
License Property
The patents cover highly predictive, metastic cancer molecular diagnostic test products, including the EP-CAM Detection Kit(TM).

These patents related to a proprietary technological product for the detection of epithelial cancer, referred to as the “EP-CAM Detection Kit.”

As a result of an acquisition, the Company now owns the rights to the following two (2) Greek patents and four (4) Greek patent applications
Greek Patent No. 1004303, issued November 6, 2002, entitled “Detection of cancer membrane antigen Ep-Cam and identification of circulating micrometastatic cancer cells in peripheral blood (and tissues) in patients with cancer of epithelial origin.”
Greek Patent No. 1004765, issued December 22, 2004 – PCT-Pending, entitled “Detection of cancer membrane antigen Ep-Cam and identification of circulating micrometastatic cancer cells in peripheral blood (and tissues) in patients with cancer of epithelial origin.”
Greek Patent Application No. 20040100269, dated July 2, 2004, entitled “Prototype RT and PCR protocols using Neowater and detection of cancer membrane antigen Ep-Cam and identification of circulating micrometastatic cancer cells in peripheral blood (and tissues) in patients with cancer of epithelial origin.”

IPSCIO Record ID: 344541

License Grant
University grants an exclusive license, with the right to sublicense, to make, have made, use, have used, import, have imported, offer for sale, have offered for sale, have sold and sell the licensed products in the United States and worldwide under the Patent rights in the Licensed Field.
License Property
The license relates to an invention(s) entitled PSMA Targeted Nanoparticles for Therapy of Prostate Cancer. PSMA is a clinically-validated tumor marker expressed on prostate cancer cells and the blood vessels of many types of non-prostate solid tumors.
Field of Use
The Licensed field shall mean all fields.  Licensee is a clinical-stage nanomedicine platform company developing novel targeted and programmable therapeutics.

IPSCIO Record ID: 203247

License Grant
University Foundation grants to Licensee an exclusive license under the Patents to make, to have made, use, offer for sale, sell and import and sell Licensed Products in the Field of Use in the Territory.

Licensor grants a non-exclusive license under the Know-How to make, to have made, use, offer for sale, sell and import and sell Licensed Products in the Field of Use in the Territory.

License Property
The Licensed Products shall mean products falling within the scope of a Valid Claim or claims of the Patents or made by processes within the scope of a Valid Claim or claims of the Patents.  The patent applications are for PSMA Binding Ligand-Linker Conjugates and Methods for Using and PSMA Binding-Ligand Conjugates and Methods for Using.

PCT/US2008/073375 8/15/2008 PSMA Binding Ligand-Linker Conjugates and Methods for Using

PCT/US2009/061067 10/16/2009 PSMA Binding-Ligand Conjugates and Methods for Using

PSMA (rostate-specific membrane antigen) is a receptor target that is predominantly over-expressed on rostate cancer cells.

Field of Use
The Field of Use shall mean All Diagnostic and Imaging Applications; and All Therapeutic Applications.  The Licensee is developing targeted therapies for the treatment of cancer and inflammatory diseases.

IPSCIO Record ID: 4246

License Grant
Licensor grants, subject to the terms of this Agreement, to Licensee a worldwide, perpetual and exclusive license to make, have made, use and create improvements to the P&O Technology, Know-How and Improvements thereto to make, have made, use, market and sell Licensed Products.
License Property
Licensee shall have the right to grant sublicenses under the license granted herein.

Licensor is the owner of certain prostate and ovarian diagnostic technology and related Know-How .

Field of Use
P&O Technology shall mean any assay developed by Licensor, or any other agent that Licensor co-operates with that utilizes antibodies against other epithelial cell growth inhibitors of the Mammastatin family of proteins for detection or measurement of a protein that has diagnostic relevance for Prostate and Ovarian Cancer. These diagnostic assays also include any assay developed by Licensor, or any other agent that Biotherapies cooperates with, that utilizes DNA sequences homologous to the Mammastatin family, and any Know-How that was possessed by Licensor at the time of this Agreement, to measure a biological marker for diagnosis of Prostate or Ovarian Cancer or measuring the risk assessment values of a subject's developing Prostate or Ovarian Cancer.

IPSCIO Record ID: 324661

License Grant
Licensor hereby grants to Norway Licensee in the Field in the Territory the following royalty-bearing exclusive (even to Licensor and its Affiliates) license (including the right to grant sublicenses) under the Licensed Technology for a Product License
(a) with respect to Licensor Patents and Licensor Know-How, to Exploit Licensed Products;
(b) with respect to the Abgenix Patents, to research, develop, make, have made, use, import, offer to sell and sell Licensed Products;
(c) with respect to the Cytogen Patents, the right and license to develop, make, have made, distribute use, offer for sale, sell, have sold, import or export Licensed Products; and
(d) with respect to the Selexis Technology, to use Cell Lines for the manufacture of Licensed and/or Final Products in the Licensed Field of Use and to research, make, have made, use, offer for sale, sell, import and otherwise exploit and commercialize Final Products manufactured using the Cell Lines, including, without limitation, the use of Licensed and Final Products in Clinical Trials (with each term used in this clause (d) as defined in the Selexis Agreement).
License Property
The license is for the development and commercialization of therapeutic antibodies combining the Licensor's prostate specific membrane antigen (PSMA) antibody technology with Licensee’s targeted thorium conjugate technology.

PSMA is a protein that has been found to be amplified on the surface of >95% of prostate cancer cells and is a validated target for the detection of primary and metastatic prostate cancer. Antibody-thorium conjugates are comprised of a radioactive alpha emitter, thorium-227, linked to an antibody, in this case PSMA. The thorium conjugates bind to the surface of tumor cells and emit alpha particles that destroy tumor cells by inducing DNA double-strand breaks, with no need for uptake into the cells for efficacy.

Antibody/ies means any and all anti-human antibodies directed against the Target that are owned or Controlled by Licensor at the Effective Date or coming within its ownership or Control during the term of this Agreement, including but not limited to the fully human antibody designated as Licensor monoclonal antibody (mAb) 006.

Conjugated Antibody means any Antibody conjugated with a functional moiety intended to be used for the chelation of an alpha-emitting radionuclide.

Licensed Product means any pharmaceutical product within the Field covered by a Licensed Patent Right or generated through the use of Licensed Know How that contains or comprises a Conjugated Antibody as an active ingredient, including, in each case, all forms, presentations, formulations, dosage forms, line extensions and modes of administration thereof.
(i)
Abgenix Notwithstanding the foregoing, with respect to the Abgenix Patent Rights, 'Licensed Product' is further defined to include only products that meet the definition above and also consist of or include one or more Antibodies (as defined in the Abgenix Agreement) that bind to the Antigen (as defined in the Abgenix Agreement) and that constitute Research Program Technology (as defined in the Abgenix Agreement).
(ii)
Cytogen For purposes of the Cytogen Patents, 'covered by a Licensed Patent' means that the manufacture, use, sale, provision or practice of a Cytogen Patent would, in the absence of a license, infringe one or more claims of a Cytogen Patent.
(iii)
Selexis Notwithstanding the foregoing, with respect to the Selexis Patents and Selexis Know-How, 'Licensed Product' is further narrowed to mean a pharmaceutical preparation in final form (including, without limitation, a targeted thorium conjugate in form of a cold kit) containing any Company Protein (as defined in the Selexis Agreement) produced using a Cell Line (as defined in the Selexis Agreement) (or an active ingredient comprising a Company Protein produced using a Cell Line) for sale by prescription, over-the-counter or any other method, in any dosage form, formulation, presentation, line extension or package configuration, including without limitation such product in development where the context so requires.

Licensed Patent Rights means the Abgenix Patents, the Cytogen Patents, the Licensor Patents and the Selexis Patents, which are, to Licensors best knowledge, listed, whereby, for the avoidance of doubt shall not be exhaustive; provided, however, does not include a list of the Abgenix Patents.

Licensor Patents means any of the following
(i) any Licensed Patent Right that is designated as Licensor Patent, and
(ii) (A) any issued patent or patent application that claims priority to and/or is a divisional, continuation, reissue, renewal, reexamination, substitution or extension of any Licensor Patent listed; (B) any patents issuing on any patent application identified in (A), including any reissues, renewals, reexaminations, substitutions or extensions thereof; and (C) any foreign counterpart of any issued patent or patent application identified in (A) or (B), whether existing at the Effective Date or thereafter (all of which shall be included as Licensor Patents), and
(iii) any Patent Right Controlled by the Licensor as of the Effective Date (other than an Abgenix Patent, Cytogen Patent or Selexis Patent) or coming under Control of Licensor during the term of the Agreement to the extent, in each case, that is related to an Antibody or useful for the Development, Manufacture or Commercialization of a Licensed Product within the Field (with the exception, however, of any Patent Right that is useful solely for the Development, Manufacture or Commercialization of an Antibody in an antibody drug conjugate other than a Conjugated Antibody).

Field of Use
This license agreement with Licensee further validates the value of Licensor's PSMA antibody technology in the development of targeted cancer treatments.

Field means the following with respect to the Licensed Product
(a)
with respect to the Licensor Know-How and the Licensor Patents, all human therapeutic (including prophylactic) indications;
(b)
with respect to the Abgenix Patents, human therapeutic, preventative (prophylactic) medical use;
(c)
with respect to the Cytogen Patents, any and all means of developing, making, having made, distributing, using, offering for sale, selling, having sold, importing or exporting any Field Antibody (as defined in the Cytogen Agreement); and
(d)
with respect to the Selexis Know-How and Selexis Patent Rights, human therapeutic, preventative (prophylactic) medical use.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.